Human TMA
| Tissue origin | % Cases with +HA staining |
| Breast | Tumour (N=117, 56%) |
| Normal (N=13, 23%) | |
| Prostate | Tumour (N=110, 46%) |
| Normal (N=17, 5.8%) | |
| Bladder | Tumour (TCC) (N=106, 43%) |
| Normal (N=8, 0%) | |
| Stomach | Tumour (adenocarcinoma) (N=95, 42%) |
| Normal (N=14, 0%) | |
| Pleura | Tumour (mesothelioma) (N=52, 37%) |
| Normal (N=15, 0%) | |
| Lung | NSCLC (N=169, 29%) |
| SCLC (N=21, 10%) | |
| Normal (N=21, 0%) | |
| Ovary | Tumour (N=185, 12%) |
| Normal (N=31, 0%) | |
| Colon | Tumour (N=136, 28%) |
| Normal (N=25, 8%) | |
| Bone marrow | Multiple myeloma (N=27, 3.7%) |
| Normal (N=35, 0%) | |
| Pancreas | Ductal adenocarcinoma (N=99, 90%) |
| Acinar cell carcinoma (N=2, 0%) | |
| Mucinous adenocarcinoma (N=5, 100%) | |
| Papillary adenocarcinoma (N=4, 25%) | |
| Squamous cell carcinoma (N=2, 100%) | |
| Normal (N=25, 4%) |
HA staining is most common in pancreatic ductal adenocarcinoma in comparison to other major human tumours.
HA, hyaluronan. TMA, tissue microarray. TCC, transitional cell carcinoma. NSCLC, non-small cell lung carcinoma. SCLC, small cell lung carcinoma.